BACKGROUND: The identification of major immunogenic peptides in multiple sclerosis (MS) is of great importance for the development of antigen-specific therapies. Cellular reactivity against a selected mix of seven myelin peptides was evaluated in vitro. The evolution of this reactivity over time and its correlation with clinical variables was also analysed. MATERIAL AND METHODS: Forty-two patients with MS, 15 with other demyelinating diseases and 40 healthy donors (HD) were studied. Cell proliferation was measured by 3[H] thymidine incorporation into samples obtained at 0, 3, 6 and 12months of MS patient follow-up. RESULTS: A positive reaction to the peptide mix was detected in 31 of the 42 patients (74%), 12 of the 40 HD (30%) and 6 of the 15 (40%) patients with other demyelinating diseases. Patients with positive proliferation had greater disability (EDSS score, 3 [1-5.5] vs. 1.0[1-2], P=0.021), higher number of relapses (7±4.1 vs. 3±1.2, P<0.001) and shorter time since the last relapse (9±7.5 vs. 32±12.3months, P=0.036). After 12months of follow-up, cell reactivity was maintained in 33 patients (78%). CONCLUSION: A high percentage of patients exhibit a significant and maintained reactivity to myelin peptides over time. Therefore, this mix may be useful as a source of antigen in the development of protocols aimed at inducing specific tolerance in MS.
BACKGROUND: The identification of major immunogenic peptides in multiple sclerosis (MS) is of great importance for the development of antigen-specific therapies. Cellular reactivity against a selected mix of seven myelin peptides was evaluated in vitro. The evolution of this reactivity over time and its correlation with clinical variables was also analysed. MATERIAL AND METHODS: Forty-two patients with MS, 15 with other demyelinating diseases and 40 healthy donors (HD) were studied. Cell proliferation was measured by 3[H] thymidine incorporation into samples obtained at 0, 3, 6 and 12months of MS patient follow-up. RESULTS: A positive reaction to the peptide mix was detected in 31 of the 42 patients (74%), 12 of the 40 HD (30%) and 6 of the 15 (40%) patients with other demyelinating diseases. Patients with positive proliferation had greater disability (EDSS score, 3 [1-5.5] vs. 1.0[1-2], P=0.021), higher number of relapses (7±4.1 vs. 3±1.2, P<0.001) and shorter time since the last relapse (9±7.5 vs. 32±12.3months, P=0.036). After 12months of follow-up, cell reactivity was maintained in 33 patients (78%). CONCLUSION: A high percentage of patients exhibit a significant and maintained reactivity to myelin peptides over time. Therefore, this mix may be useful as a source of antigen in the development of protocols aimed at inducing specific tolerance in MS.
Authors: M J Mansilla; S Presas-Rodríguez; A Teniente-Serra; I González-Larreategui; B Quirant-Sánchez; F Fondelli; N Djedovic; D Iwaszkiewicz-Grześ; K Chwojnicki; Đ Miljković; P Trzonkowski; C Ramo-Tello; E M Martínez-Cáceres Journal: Cell Mol Immunol Date: 2021-05-06 Impact factor: 22.096
Authors: Anja Ten Brinke; Marc Martinez-Llordella; Nathalie Cools; Catharien M U Hilkens; S Marieke van Ham; Birgit Sawitzki; Edward K Geissler; Giovanna Lombardi; Piotr Trzonkowski; Eva Martinez-Caceres Journal: Front Immunol Date: 2019-02-22 Impact factor: 7.561
Authors: Judith Derdelinckx; María José Mansilla; Maxime De Laere; Wai-Ping Lee; Juan Navarro-Barriuso; Inez Wens; Irene Nkansah; Jasmijn Daans; Hans De Reu; Aneta Jolanta Keliris; Johan Van Audekerke; Verdi Vanreusel; Zoë Pieters; Annemie Van der Linden; Marleen Verhoye; Geert Molenberghs; Niel Hens; Herman Goossens; Barbara Willekens; Patrick Cras; Peter Ponsaerts; Zwi N Berneman; Eva María Martínez-Cáceres; Nathalie Cools Journal: J Neuroinflammation Date: 2019-08-15 Impact factor: 8.322
Authors: Laia Grau-López; Maria Luisa Granada; Dàlia Raïch-Regué; Mar Naranjo-Gómez; Francesc E Borràs-Serres; Eva Martínez-Cáceres; Cristina Ramo-Tello Journal: BMC Neurol Date: 2012-09-24 Impact factor: 2.474
Authors: Barbara Willekens; Silvia Presas-Rodríguez; Nathalie Cools; Cristina Ramo-Tello; M J Mansilla; Judith Derdelinckx; Wai-Ping Lee; Griet Nijs; Maxime De Laere; Inez Wens; Patrick Cras; Paul Parizel; Wim Van Hecke; Annemie Ribbens; Thibo Billiet; Geert Adams; Marie-Madeleine Couttenye; Juan Navarro-Barriuso; Aina Teniente-Serra; Bibiana Quirant-Sánchez; Ascensión Lopez-Diaz de Cerio; Susana Inogés; Felipe Prosper; Anke Kip; Herman Verheij; Catharina C Gross; Heinz Wiendl; Marieke Sm Van Ham; Anja Ten Brinke; Ana Maria Barriocanal; Anna Massuet-Vilamajó; Niel Hens; Zwi Berneman; Eva Martínez-Cáceres Journal: BMJ Open Date: 2019-09-09 Impact factor: 2.692